#### Supplementary Table 1. Summary of patients’ characteristics and treatment details

| Patient no. | Age, yr | Sex | Tumor grade | Metastatic sites | Previous treatment | Ki-67 index, % | Cycles of CAPTEM | Temozolomide dose, mg | Capacitabine dose, mg | Best response | OS, mo | PFS, mo |
|-------------|---------|-----|-------------|------------------|--------------------|----------------|-------------------|----------------------|----------------------|--------------|--------|--------|
| 1           | 42      | Female | NET, grade2 | Liver            | -                  | 3              | 46                | 300                  | 1,000                | PR           | 65.3   | 54.17  |
| 2           | 59      | Male  | NET, grade2 | Liver            | -                  | 8              | 2                 | 300                  | 1,150                | SD           | 44.5   | 44.5   |
| 3           | 38      | Male  | NET, grade2 | Liver, lymph node | -                  | 12             | 5                 | 300                  | 1,150                | SD           | 8.97   | 3.57   |
| 4           | 66      | Female | NET, grade2 | Liver            | Surgery            | 6.76           | 7                 | 300                  | 1,000                | PR           | 7.07   | 7.07   |
| 5           | 49      | Female | NET, grade2 | Liver, lymph node | -                  | 4              | 10                | 300                  | 1,150                | SD           | 41.17  | 10.47  |
| 6           | 72      | Male  | NET, grade2 | Liver, lymph node, mediastinum | - | 5 | 25 | 300 | 1,150 | SD | 41.43 | 39.7  |
| 7           | 63      | Male  | NET, grade3 | Liver            | Surgery, TACE      | 40             | 3                 | 300                  | 1,150                | PD           | 31.47  | 2.37   |
| 8           | 74      | Female | NET, grade3 | Lymph node, bone | Chemotherapy (EP, IP) | 88.5 | 2 | 300 | 1,300 | PD | 15.87 | 2.77 |
| 9           | 60      | Female | NET, grade3 | Liver            | Surgery            | 30             | 21                | 300                  | 1,150                | PR           | 23.73  | 23.73  |
| 10          | 51      | Female | NEC          | Liver, lymph node | Surgery, chemotherapy (EP, IP) | 90 | 5 | 350 | 1,300 | PR | 11.2  | 4.6   |
| 11          | 69      | Female | NEC          | Liver, lymph node, adrenal gland | Chemotherapy (EP, IP) | 80 | 2 | 300 | 1,500 | PD | 3.23  | 2.07  |
| 12          | 67      | Male  | NEC          | Liver, lymph node, peritoneum | Surgery, chemotherapy (EP) | 40 | 4 | 370 | 1,300 | SD | 5.47  | 3.73  |

CAPTEM, capecitabine and temozolomide; OS, overall survival; PFS, progression-free survival; NET, neuroendocrine tumor; PR, partial response; SD, stable disease; TACE, transarterial chemoembolization; PD, progressive disease; EP, etoposide+ cisplatin chemotherapy; IP, irinotecan+ cisplatin chemotherapy; NEC, neuroendocrine carcinoma.